| Kaitanni (cadonilimab) / Akesobio |
NCT03261011: Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors |
|
|
| Unknown status | 1a/1b | 153 | RoW | AK-104 | Akesobio Australia Pty Ltd | Advanced Cancer | 03/20 | 09/20 | | |
NCT04572152: A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1a/1b | 23 | RoW | AK119, AK104 | Akeso | Advanced or Metastatic Solid Tumors | 12/22 | 10/23 | | |
NCT05868876: A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1a/1b | 205 | RoW | AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion | Akeso | Advanced Malignant Tumors | 11/25 | 02/26 | | |
AK117-101, NCT04349969: A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104 |
|
|
| Completed | 1 | 50 | RoW | AK117, AK117+AK104 | Akesobio Australia Pty Ltd | Neoplasms Malignant | 11/22 | 11/22 | | |
NCT05559554: A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects |
|
|
| Completed | 1 | 100 | RoW | AK104 (before the change), AK104 (after the change) | Akeso | Healthy Male Subjects | 03/23 | 04/23 | | |
NCT05737368: Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab |
|
|
| Not yet recruiting | 1 | 11 | NA | fractionated radiotherapy, cadonilimab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recurrent Glioblastoma | 02/24 | 02/25 | | |
NCT05856864: Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy |
|
|
| Recruiting | 1 | 30 | RoW | Cadonilimab Injection, AK104, Ramucirumab Injection | Tianjin Medical University Cancer Institute and Hospital | Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy | 07/24 | 05/25 | | |
| Not yet recruiting | 1 | 60 | RoW | AK104+Axitinib, Cadonilimab, AK112+Axitinib, Ivonescimab | Peking University Cancer Hospital & Institute | Melanoma, Mucosal Melanoma, Metastatic Melanoma | 12/25 | 12/27 | | |
NCT05021120: A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours |
|
|
| Recruiting | 1 | 143 | RoW | AK127, AK104 | Akesobio Australia Pty Ltd | Advanced or Metastatic Solid Tumours | 01/25 | 04/25 | | |
NCT05644379: A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 30 | RoW | Cadonilimab Injection, AK104, Regorafenib | Tianjin Medical University Cancer Institute and Hospital | Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy | 11/25 | 11/25 | | |
NCT05644392: A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours |
|
|
| Recruiting | 1 | 30 | RoW | Cadonilimab Injection, AK104, Regorafenib | Tianjin Medical University Cancer Institute and Hospital | Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy | 11/25 | 11/25 | | |
